News for WuXi Biologics (Cayman) Inc. (2269.HK)

WuXi Biologics (2269.HK) successfully completes a commercial PPQ campaign using Asia's first 5,000L bioreactors. The new system reduced protein producti

PR NewswireSHANGHAI, April 14, 2025 SHANGHAI, April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Dev

PR NewswireHONG KONG, March 25, 2025 Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoYAdjusted EBITDA grew 14.4% YoY to RM

Revenue grew 9.6% YoY to RMB 18,675.4 million, with non-COVID revenue up 13.1% YoY Adjusted EBITDA grew 14.4% YoY to RMB7,999.3 million and Adjusted Net Profit increased 9.0% YoY to RMB5,396.9 million Added 151 new integrated projects, including 13 in late-stage and commercial stage Total integrated projects reached 817, one of the largest portfolios of complex biologics Research Services enabled 7 global programs for molecule discovery, eligible to receive ~$140 million in near-term payments Completed 16 PPQs in 2024, with 24 PPQs scheduled for 2025 Strengthened global presence to support continued business momentum HONG KONG, March 25, 2025 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ('WuXi Biologics' or 'the Group', stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its audited annual results for the year ended December 31, 2024 ('Reporting Period').

PR NewswireSHANGHAI, March 23, 2025 SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Dev

PR NewswireSHANGHAI, March 20, 2025 Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6)Contributin

Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) Contributing to the 2025 World Water Day campaign to ensure the availability of water and sanitation for all SHANGHAI, March 21, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by the environmental non-profit CDP for leadership in corporate transparency and performance on water security, securing a place on the organization's annual 'A List' for the second year.

Ranking in top 1% of S&P Global CSA Score Inclusion in Global Yearbook for third consecutive year Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 11, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in the S&P Global Sustainability Yearbook 2025 ('Yearbook') for its strong sustainability performance in 2024. The company was ranked top in its industry and received a Top 1% S&P Global Corporate Sustainability Assessment (CSA) Score, marking the third year WuXi Biologics has received this highest level of recognition.

PR NewswireHANGZHOU, China, March 3, 2025 - EffiXâ„¢ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli

- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe

WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities (MFG2 and MFG5), in Wuxi city.

PR NewswireSHANGHAI, Feb. 18, 2025 Ranked among the top 1% of more than 150,000 companies across 185 countriesTrusted by global partners for strong sustain

Ranked among the top 1% of more than 150,000 companies across 185 countries Trusted by global partners for strong sustainability commitment Recognized as a leader in Green CRDMO, driving innovation for a healthier future SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been awarded a Platinum Medal by the EcoVadis Sustainability Rating, marking the second year the company has received the rating's highest level of recognition.

PR NewswireSHANGHAI, Feb. 10, 2025 Ranked among the top 1% of companies assessed in the pharmaceutical industryRecognized as a leader in Green CRDMO, drivi

Ranked among the top 1% of companies assessed in the pharmaceutical industry Recognized as a leader in Green CRDMO, driving innovation for a healthier future Committed to creating long-term value for all stakeholders SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized as a 2025 Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics, marking the fifth consecutive year the company has scored among the highest in ESG Risk Ratings.

PR NewswireSHANGHAI and SAN DIEGO, Jan. 6, 2025 SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading glob

WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-cell Engager

Named for second consecutive year named to prestigious DJSI list Leading green biologics solutions for a healthier future SHANGHAI, Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the 2024 Dow Jones Sustainability Indices (DJSI), and given among the top scores for its unremitting efforts and notable achievements in promoting sustainable development.

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO ® and $100 Million PIPE Financing